Camk2d antisense oligonucleotides and uses thereof
AssigneesBristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
InventorsRichard E. OLSON, Brian R. ANDERSON, Peter HAGEDORN, Marianne Lerbech JENSEN, Ivar M. MCDONALD, Stephen E. MERCER
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.
Claims36
An antisense oligonucleotide (ASO) comprising a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is at least about 80% complementary to a nucleic acid sequence within a calcium/calmodulin-dependent protein kinase type II delta (CAMK2D) transcript.
(canceled)
5-7. (canceled)
9-11. (canceled)
(canceled)
(canceled)
(canceled)
21-22. (canceled)
24-32. (canceled)
35-36. (canceled)
(canceled)
40-43. (canceled)
(canceled)
(canceled)
49-51. (canceled)
53-56. (canceled)
58-61. (canceled)
Dependencies are inferred from the claim text.